CClinicalTrials.gg
CompletedNCT01394289Updated Aug 27, 2012

Biological Standardization of Lolium Perenne Allergen Extract

A Phase 2 interventional study of Lolium allergen extract in Allergy to Grass Pollen, sponsored by Laboratorios Leti, S.L.. Completed at 2 sites in Spain. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2012-08-27.

Sponsored by Laboratorios Leti, S.L. · Phase 2, Interventional, and Diagnostic

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The objective of this study is to determine the biologic activity of a Lolium perenne allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

Read the detailed description

Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm.

02

Conditions studied

  • Allergy to Grass Pollen

Keywords

  • Standardization
  • Immunotherapy
  • Skin prick test
03

In context

Lead sponsor

Laboratorios Leti, S.L. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject has provided written informed consent, appropriately signed and dated by the subject (or legal representative, if applicable).
  • Subject can be male or female of any race and ethnic group.
  • Age > 18 years and \< 50 years at the study inclusion day.
  • Positive skin prick test with a standardized commercially available preparation of Lolium perenne allergen extract. The skin prick test will be considered positive if the test results in a wheal major diameter of at least 3 mm and at least the size of the positive control. Positive skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study
  • A positive test for specific IgE to Lolium perenne (CAP-RAST ≥ 2). IgE results are valid if performed within one year prior to the inclusion of the subject in the study.
  • Allergic symptoms during the pollen season of Lolium perenne.
  • Mean of the forearm major diameters of the wheals provoked by histamine dihydrochloride (10 mg/ml) ≥ 3 mm.

Exclusion criteria

Exclusion Criteria:

  • Immunotherapy in the past 5 years with an allergen preparation known to interfere with the allergen to be tested (e.g., grass group extracts).
  • Use of drugs that may interfere with the skin reactions (e.g., antihistamines). See Appendix 1
  • Treatment with any of the following medications: tricyclic or tetracyclic antidepressants, β-blockers or corticosteroids (> 10 mg/day of prednisone or equivalent).
  • Pregnancy.
  • Dermographism affecting the skin area at the test site at either study visit.
  • Atopic dermatitis affecting the skin area at the test site at either study visit.
  • Urticaria affecting the skin area at the test site at either study visit.
  • Participation in another clinical trial within the last month.
05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Biological/Vaccine: Lolium allergen extract

    Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.

    Biological: Lolium allergen extract

Interventions

  • BiologicalLolium allergen extract

    This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines. Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.

06

What researchers measure

Primary outcomes

  1. Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase.

    Time frame: 30 minutes per subject

07

Study locations

2 sites
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen del Rocío
    Sevilla, 41013, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01394289
Lead sponsor
Laboratorios Leti, S.L.
Responsible party
Sponsor
First posted
Jul 14, 2011
Start date
Sep 2011
Primary completion
Nov 2011
Completion
Nov 2011
Last update
Aug 27, 2012

Study contacts

María José Gómez
study chair · Laboratorios LETI, S.L.U

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion